Open company graph database — free web & API
Login

NRL Pharma Inc.

株式会社NRLファーマNRL Pharma, Inc.Alias
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
4
§01

Basic information

BASIC
Head office
11F Gotenyama Trust Tower, 4-7-35 Kitashinagawa, Shinagawa-ku, Tokyo 140-0001, JapanSources
Chief executive
Masao KakutaSources
Capital
64,000,000
Employees (non-consolidated)
Employees (consolidated)
Start date
1998-04-23
End date
§02

Websites

1 DOMAINS
§03

Business

3
1. Research, development, manufacturing, and sale of health foods and food ingredients such as lactoferrin (LF), or manufacturing, selling, and planning products under partner brands.Sources2. Research, development, manufacturing, and sale of cosmetics and the sale of their results.Sources3. Research, development, sale of pharmaceuticals and quasi-drugs, and the sale and manufacturing of their results.Sources
§04

Related companies

4 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Japan Preventive Medicine Co., Ltd. Sources
Group
BB Laboratories Inc. Sources
Group
Sohiken Holdings Co., Ltd. Sources
Group
General Medical Science Research Institute Inc. Sources
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

87 EVENTS

Establishment of NRL Pharma Inc.Sources

1998 : Founded by Tamura Gakuzo, Ando Kunio, and others as Nuclear Receptor Research Institute Co., Ltd.Sources

Foundation : 1998年4月23日 : April 23, 1998Sources

Development of enteric-coated lactoferrin and launch as a health supplement (supplement).Sources

2000 : Developed enteric-coated lactoferrin and began selling it as a health supplement (supplement).Sources

Discovery of lactoferrin’s lipid metabolism improvement effect through joint research with Tottori University.Sources

2001 : Discovered lactoferrin's lipid metabolism improvement effect through joint research with Tottori University.Sources

Discovery of lactoferrin’s analgesic and anxiolytic effects through joint research with Tottori University.Sources

2002 : Discovered lactoferrin's analgesic and anxiolytic effects through joint research with Tottori University.Sources

Death of Gakuzo Tamura (December).Sources

2002 : Tamura Gakuzo passed away (December).Sources

Renamed company to NRL Pharma Inc.Sources

Creation of a new imino derivative of third-generation Ascochlorin.Sources

Launch of "Lactoferrin G" containing 50mg lactoferrin per tablet.Sources

2003 : Renamed the company to NRL Pharma Co., Ltd.Sources

2003 : Created a third-generation ascorclorine novel imino derivative.Sources

2003 : Launched "Lactoferrin G", a 50 mg lactoferrin per tablet.Sources

Creation of a new acetyl derivative of third-generation Ascochlorin.Sources

Launch of hard capsule "Lactoferrin D" containing lactoferrin.Sources

2004 : Created a third-generation ascorclorine novel acetyl derivative.Sources

2004 : Launched hard capsule "Lactoferrin D" containing lactoferrin.Sources

Obtained a use patent for "lactoferrin’s lipid metabolism improvement effect".Sources

Successfully developed enteric-coated lactoferrin granules.Sources

Discovery of lactoferrin’s heavy metal damage improvement effect through joint development with Jikeikai Medical University.Sources

2005 : Obtained a use patent for "Lactoferrin's lipid metabolism improvement effect."Sources

2005 : Successfully developed enteric-coated lactoferrin granules.Sources

2005 : Discovered "Lactoferrin's heavy metal damage improvement effect" through joint development with Jikeikai Medical University.Sources

Obtained a use patent for "lactoferrin’s analgesic and anxiolytic effects".Sources

2006 : Obtained a use patent for "Lactoferrin's analgesic and anxiolytic effects."Sources

Obtained a patent for "lactoferrin complexes and their manufacturing methods".Sources

Obtained a patent for "frequent urination improvement agents and compositions containing them, including pharmaceuticals and foods".Sources

Obtained a patent for "matrix-type enteric-coated, sustained-release compositions".Sources

First full-year profitability after founding.Sources

Launch of "Lactoferrin GX" containing 100mg lactoferrin per tablet.Sources

2008: Patent obtained for "Lactoferrin complex and its method of manufacture."Sources

2008: Patent obtained for "Antidiuretic agent and pharmaceutical compositions and foods containing it."Sources

2008: Patent obtained for "Matrix-type enteric-coated, sustained-release composition."Sources

2008: First full-year profit achieved after founding.Sources

2008: "Lactoferrin GX" containing 100 mg of lactoferrin per tablet launched.Sources

License granted to a company for a lipid metabolism‑improving composition and lactoferrin enteric‑coated processing technology patent.Sources

Patent obtained for "Lactoferrin complex and its manufacturing method (PEG‑lactoferrin)".Sources

Patent obtained for a novel pharmaceutical composition to treat or prevent dry eye.Sources

Patent obtained for an anti‑ageing eye disease improvement agent.Sources

Launch of "Lactoferrin Moist" containing lactoferrin and cosmetic ingredients.Sources

2009: Licensed the rights to a lipid metabolism improvement composition and lactoferrin enteric processing technology patent to a company.Sources

2009: Patent obtained for "Lactoferrin complex and its method of manufacture (PEG lactoferrin)."Sources

2009: Patent obtained for "Novel pharmaceutical composition for treating or preventing dry eye."Sources

2009: Patent obtained for "Age-related eye disease improvement agent."Sources

2009: "Lactoferrin Moist" launched, a lactoferrin product with cosmetic ingredients.Sources

Selected for the 2010 Industrial Property Utilization Excellence Award (Minister of Economy, Trade and Industry).Sources

Received the Innovation Encouragement Award from the Innovation Association at the 2010 Kanto Regional Innovation Awards.Sources

Obtained a Japanese patent for Lactoferrin "Method and Use for Producing a New Food that Improves Quality of Life (Enteric Coating)."Sources

Launched the Lactoferrin‑infused granule product "Lactoferrin Soy Milk Granules."Sources

Launched the adhesive type "Raku Patch."Sources

Obtained a patent for Ascochlorin "New Transcription Factor, Its Production Method and Use (Acetylated Derivative)."Sources

2010: Selected as an excellent enterprise for utilizing industrial property rights in fiscal 2010 by the Minister of Economy, Trade and Industry (Patent Utilization Excellence Award).Sources

2010: Received the Innovation Encouragement Award from the Japan Innovation Association at the Kanto Regional Innovation Awards.Sources

2010: Japanese patent obtained for "Method of manufacturing and use of lactoferrin for improving quality of life (enteric-coated agent)."Sources

2010: "Lactoferrin soy milk granules" launched.Sources

2010: "Lac Patch" adhesive type product launched.Sources

2010: Patent obtained for "Ascorclorin new transcription factor, its method of manufacture and use (acetylated derivative)."Sources

Obtained a patent for Ascochlorin "New Transcription Factor, Its Production Method and Use (Imine Derivative)."Sources

Launched the chewable tablet "Lactoferrin Oral Fresh."Sources

2011: Patent obtained for "Ascorclorin new transcription factor, its method of manufacture and use (imino derivative)."Sources

2011: "Lactoferrin Oral Fresh" chewable tablet containing lactoferrin launched.Sources

Kuniaki Ando passed away (July).Sources

2011: Mr. Kunio Ando passed away (July).Sources

Received the Agricultural and Chemical Technology Award jointly with Lion Corporation from the Japan Society of Agricultural and Biological Chemistry for developing a lactoferrin‑containing functional food focusing on enteric processing technology.Sources

Obtained a patent for Lactoferrin "New Pharmaceutical Composition for Treating or Preventing Dry Eye and Processed Food."Sources

Obtained a patent for "Pharmaceutical Composition and Processed Food Containing Lactoferrin (Menstrual Pain Relief Effect)."Sources

2012: Awarded the Japan Agricultural and Chemical Society Agricultural and Chemical Technology Award jointly with Lion Corporation for developing a lactoferrin-containing functional food focusing on enteric processing technology.Sources

2012: Patent obtained for "novel pharmaceutical compositions and processed foods containing lactoferrin for the treatment or prevention of dry eye."Sources

2012: Patent obtained for "pharmaceutical compositions containing lactoferrin and processed foods (menstrual pain relief effect)."Sources

Obtained a patent for "Lactoferrin Fusion Protein and Its Production Method (Fc‑LF Fusion)."Sources

2015: Patent obtained for "lactoferrin fusion proteins and their manufacturing methods (Fc-LF fusion)."Sources

Obtained a patent for Lactoferrin "Pharmaceutical Composition and Food for Improving Menopause Disorders."Sources

Patent obtained for the micro-particle production method of lactoferrin.Sources

2016: Patent obtained for "pharmaceutical compositions and food products for improving menopausal disorders containing lactoferrin."Sources

2016: Patent obtained for "manufacturing method of micro-sized lactoferrin particles."Sources

Enter the umbrella of Sōyiken Holdings Co., Ltd.Sources

Oral Care Chewable Series Products, "Lactoferrin Oral Wet" and "Lactoferrin Oral Periblock" Launch.Sources

Astaxanthin Preparation, Eye Focus Adjustment Supplement "HAEMATOP" (Functional Claim Receipt) Launch.Sources

2017: Became a subsidiary of Sumiyoken Holdings Co., Ltd."Sources

2017: Launch of Oral Care Chewable Series products "Lactoferrin Oral Wet" and "Lactoferrin Oral Periblock."Sources

2017: Launch of astaxanthin formulation, eye focus adjustment supplement "HAEMATOP" (functional food notification received).Sources

Patent Granted for Lactoferrin as "Inhibitor of Extracellular Trapping Formation in White Blood Cells".Sources

2018: Patent obtained for "inhibitor of extracellular trap formation by leukocytes containing lactoferrin."Sources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑